1-N,4-N-di(pyrrol-1-yl)cyclohexa-2,5-diene-1,4-diimine | 55872-82-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-N,4-N-di(pyrrol-1-yl)cyclohexa-2,5-diene-1,4-diimine
• 英文别名: anti-N,N'-(2,5-cyclohexadiene-1,4-diylidene)bis-1H-pyrrol-1-amine
• CAS: 55872-82-7；79381-19-4；79381-25-2
• 化学式: C₁₄H₁₂N₄
• 分子量: 236.276
• InChiKey: VQKVZNAYFUDTTE-VCFJNTAESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.52
• 重原子数：
  18.0
• 可旋转键数：
  2.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.58
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  1-N,4-N-di(pyrrol-1-yl)cyclohexa-2,5-diene-1,4-diimine 在 sodium dithionite 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以95%的产率得到N,N'-二(1H-吡咯-1-基)-1,4-苯二胺
  参考文献：
  名称：

  Synthesis and antibacterial activity of 1-(arylamino)-1H-pyrroles and 4-(1H-pyrrol-1-ylimino)-2,5-cyclohexadienes

  摘要：

  The syntheses of 1-(arylamino)-1H-pyrroles and 4-(1H-pyrrol-1-ylimino)-2-5-cyclohexadienes are described. Several of these compounds express in vitro antibacterial activity or can be metabolized to show in vitro antibacterial activity, and a few examples have shown efficacy against tuberculosis in mice. One compound, N,N'-(2,5-cyclohexadiene-1,4-diylidene)bis-1H-pyrrol-1-amine, is completely effective at 6.25 mg/kg against Mycobacterium tuberculosis H37Rv.

  DOI：

  10.1021/jm00143a011
• 作为产物：
  描述：

  1-氨基吡咯 、 对苯醌 在 三氟乙酸 作用下， 以 乙醚 为溶剂， 以42%的产率得到1-N,4-N-di(pyrrol-1-yl)cyclohexa-2,5-diene-1,4-diimine
  参考文献：
  名称：

  Synthesis and antibacterial activity of 1-(arylamino)-1H-pyrroles and 4-(1H-pyrrol-1-ylimino)-2,5-cyclohexadienes

  摘要：

  The syntheses of 1-(arylamino)-1H-pyrroles and 4-(1H-pyrrol-1-ylimino)-2-5-cyclohexadienes are described. Several of these compounds express in vitro antibacterial activity or can be metabolized to show in vitro antibacterial activity, and a few examples have shown efficacy against tuberculosis in mice. One compound, N,N'-(2,5-cyclohexadiene-1,4-diylidene)bis-1H-pyrrol-1-amine, is completely effective at 6.25 mg/kg against Mycobacterium tuberculosis H37Rv.

  DOI：

  10.1021/jm00143a011

文献信息

• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• [EN] DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF<br/>[FR] LIQUIDES IONIQUES À DOUBLE FONCTION ET SELS DE CEUX-CI
  申请人：UNIV ALABAMA

  公开号：WO2010078300A1

  公开（公告）日：2010-07-08

  Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are 'solvated,' for example, 'hydrated' and their uses.

  本文揭示了包括活性药物、生物学和营养化合物的离子液体组合物，以及其使用方法。进一步揭示了包括液态离子对的物质组合物，单独或溶解后使用；以及离子液体的“溶剂化”组合物，例如“水合”的组合物及其用途。
• Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
  申请人：Mueller A. Richard

  公开号：US20050119310A1

  公开（公告）日：2005-06-02

  Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immuno-stimulating agents.

  提供了一种治疗哺乳动物，尤其是人类肝炎病毒感染的方法和组合物。该方法包括（1）单独或与核苷类抗病毒药物、核苷酸类抗病毒药物、二者的混合物或免疫调节/免疫刺激剂结合使用N-取代-1,5-二脱氧-1,5-亚氨基-D-葡萄糖醇化合物，或（2）单独或与核苷类抗病毒药物、核苷酸类抗病毒药物、或二者的混合物以及免疫调节/免疫刺激剂结合使用N-取代-1,5-二脱氧-1,5-亚氨基-D-葡萄糖醇化合物。
• Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
  申请人：Mueller A. Richard

  公开号：US20050267153A1

  公开（公告）日：2005-12-01

  Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immuno-stimulating agents.

  提供了用于治疗哺乳动物，尤其是人类乙型肝炎病毒感染的方法和组合物。该方法包括（1）单独或与核苷类抗病毒药物、核苷酸类抗病毒药物、它们的混合物或免疫调节/免疫刺激剂结合使用N-取代-1,5-二脱氧-1,5-亚胺-D-葡萄糖醇化合物，或（2）单独或与核苷类抗病毒药物、核苷酸类抗病毒药物或它们的混合物以及免疫调节/免疫刺激剂结合使用N-取代-1,5-二脱氧-1,5-亚胺-D-葡萄糖醇化合物。
• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。